quinazolines has been researched along with icotinib in 169 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (1.18) | 29.6817 |
| 2010's | 133 (78.70) | 24.3611 |
| 2020's | 34 (20.12) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Guan, Z; Wang, Y; Zhong, D | 1 |
| Hu, P; Jiang, J; Liu, D; Tan, F; Wang, Y | 1 |
| Liu, D; Shentu, J; Tan, F; Wang, Y; Xu, N; Yang, G; Yao, Y; Zhao, Q; Zhou, J | 1 |
| Ren, GJ; Shan, B; Xiao, Y; Xu, JS; Zhang, L; Zhao, YY; Zhu, YJ | 1 |
| Hu, P; Jiang, J; Liu, D; Tan, F; Wang, Y; Zhang, L | 1 |
| Hu, P; Jiang, J; Ren, GJ; Tan, FL; Wang, HP; Wang, MZ; Wang, YX; Xia, Y; Xiao, Y; Zhang, L | 1 |
| Ding, L; He, W; Hu, Y; Shen, X; Tan, F; Wang, D; Wang, Y; Xie, G; Zhang, X | 1 |
| Yang, G; Yao, Y; Zhao, Q; Zhou, J | 1 |
| Hu, P; Jiang, J; Liu, DY; Ruan, CJ | 1 |
| Guo, Z; Li, J | 1 |
| Shi, YK | 1 |
| Han, XH; Ma, L; Shi, YK; Wang, JF; Wang, S | 1 |
| Li, X; Lü, JL; Qin, N; Sun, YF; Wu, YH; Yang, XJ; Zhang, H; Zhang, Q; Zhang, SC | 1 |
| Wang, B; Wang, YN; Zhao, Q | 1 |
| Cai, J; He, C; Lin, B; Shao, L; Song, Z; Yu, X; Zhang, B; Zhang, Y | 1 |
| Hou, K; Hu, X; Kang, J; Liu, Y; Mu, X; Qu, X; Zhang, Y | 1 |
| Chen, G; Guo, Y; Li, Z; Liu, H; Wang, Y; Zhang, L | 1 |
| Cai, P; Chen, W; Fang, X; Gao, Z; Gu, Y; Sun, Y; Xu, Q; Zhang, X | 1 |
| Bai, H; Chen, J; Fang, F; Fang, J; Feng, Q; Feng, Y; Li, S; Lv, C; Ma, Y; Pei, Y; Wang, J; Wang, Y; Wu, N; Yan, S; Yang, Y; Zhao, B; Zheng, Q | 1 |
| Lv, J; Nong, J; Qin, N; Wang, J; Wu, Y; Yang, X; Zhang, H; Zhang, Q; Zhang, S | 1 |
| Li, X; Lv, J; Nong, J; Qin, N; Wu, Y; Yang, X; Zhang, H; Zhang, Q; Zhang, S | 1 |
| Camidge, DR | 1 |
| Bai, C; Chen, J; Cheng, Y; Dai, H; Ding, L; Feng, J; Hu, C; Jiao, S; Jin, Y; Li, Q; Liang, L; Liu, W; Liu, X; Luo, R; Qin, S; Shi, Y; Song, Y; Sun, Y; Tan, F; Wang, D; Wang, J; Wang, Y; Wei, Z; Wu, YL; Xu, N; Zhang, H; Zhang, L; Zhang, S; Zhang, W; Zhang, Y; Zhou, C; Zhou, J | 1 |
| Ding, JF; Zhong, DF | 1 |
| Guan, Y; Jiao, S; Meng, J; Yan, X; Zhao, H | 1 |
| He, C; Lin, B; Lou, G; Shao, L; Song, Z; Yu, X; Zhang, B; Zhang, Y | 1 |
| Hu, P; Jiang, J; Liu, D; Tan, F; Wang, Y; Zhang, D; Zhang, L | 1 |
| Dinglin, X; Fang, W; Hou, X; Hu, Z; Huang, P; Huang, Y; Liang, W; Ma, Y; Qin, T; Tian, Y; Wu, X; Xue, C; Yan, Y; Yang, Y; Zhang, J; Zhang, L; Zhao, H; Zhao, Y; Zhou, T | 1 |
| Guan, YS; He, Q; Li, M | 1 |
| Chen, X; Fan, L; Fei, K; Gao, G; He, Y; Li, A; Li, J; Li, S; Li, W; Li, X; Ren, S; Schmid-Bindert, G; Shi, J; Zhao, C; Zhou, C | 1 |
| Fang, H; Huang, S; Li, S; Liu, R; Pan, H; Wang, Z; Zhou, J | 1 |
| Chen, X; Gu, Y; Guo, R; Liu, L; Liu, P; Liu, Y; Lu, K; Røe, OD; Shu, Y; Wang, J; Wang, Z; Yin, Y; Zhu, L; Zhu, Q | 1 |
| Ambudkar, SV; Bates, SE; Chen, ZS; Kathawala, RJ; Patel, A; Robey, RW; Shukla, S; Talele, TT; Wang, DS; Wang, YJ; Xu, RH; Yang, DH; Zhang, L; Zhang, YK | 1 |
| Song, Z; Wu, W; Zhang, Y | 1 |
| Cui, W; Lu, D; Ren, M; Yan, J; Yang, C; Yuan, G; Zhang, Y | 1 |
| Chen, J; Hu, P; Jiang, J; Liu, DY; Tan, FL; Wang, YX; Wu, YW; Zhao, Q; Zheng, X | 1 |
| Ding, L; Gu, A; Han, B; He, J; Hu, X; Jia, X; Jiao, SC; Ma, K; Peng, J; Sun, Y; Tan, F; Wang, CL; Wang, J; Wang, Y; Wu, M; Ying, K; You, C; Zhang, L; Zhang, S; Zhang, Y | 1 |
| Cui, J; Guo, QQ; Han, LL; Jiang, LL; Jing, L; Liang, X; Liu, Y; Liu, ZY; Ma, JQ; Nan, KJ; Wang, J; Wang, MC; Wu, T; Yang, CC; Yao, Y | 1 |
| Gao, Z; Gu, Y; Guo, L; Guo, W; Hong, S; Shen, Y; Sun, Y; Wu, X; Xu, Q | 1 |
| Guo, S; Li, Z; Liu, Y; Ren, G; Ren, J; Song, G; Wang, Y; Zhang, L | 1 |
| Chen, H; Du, N; Li, F; Yang, P; Zhao, X; Zhu, G | 1 |
| Chen, Y; Liu, J; Wang, C; Wang, M; Zhang, L; Zhao, X | 1 |
| Bi, J; Ke, Y; Liu, T; Ma, H; Zhang, S; Zhang, T | 1 |
| Ding, L; Shi, Y; Sun, Y; Tan, F; Wang, Y; Yuan, X | 1 |
| Hu, HG; Huang, JJ; Shen, H; Zhao, J | 1 |
| Chen, J; Hu, P; Jiang, J; Liu, D; Zhao, Q; Zheng, X | 2 |
| Ai, YQ; He, WJ; Li, RQ; Li, WH; Li, YF; Wang, Y; Xia, YX; Zhang, J; Zhao, PZ | 1 |
| Li, Y; Qian, K; Wang, R; Yao, S; Zhang, Y | 1 |
| Fan, Y; Gong, L; Huang, Z; Miao, L; Xiong, M | 1 |
| Fan, Y; Fang, L; Gong, L; Huang, Z; Lei, T; Mao, W; Miao, L; Yang, H; Yu, H | 1 |
| Hu, P; Jiang, J; Liu, D; Liu, Y; Tan, F; Wang, Y; Wu, Y; Zhang, L | 1 |
| Chen, Q; Ding, L; Hong, X; Liang, Y; Quan, Q; Wu, H; Zhou, N | 1 |
| Bai, C; Chen, G; Ding, C; Feng, J; Gu, A; Han, B; He, J; Huang, C; Jian, H; Jiao, S; Li, F; Ling, Y; Liu, X; Luo, H; Luo, R; Pang, Q; Shi, Y; Shu, Y; Sun, Y; Wang, C; Wang, Z; Wu, M; Yang, Y; Zhang, S; Zhang, Y; Zhao, H; Zhao, Q; Zhou, C; Zhou, Y | 1 |
| Huang, XE; Shi, B; Xu, J; Zhang, XB | 1 |
| Hu, B; Jiang, J; Li, C; Liu, DY; Ni, J; Wang, HP; Zhang, L | 1 |
| Cao, M; Chen, H; Chu, Q; Han, R; He, Y; Sun, J; Wang, D; Wang, Y; Yao, W | 1 |
| Cai, K; Feng, S; Wang, H; Wang, Y; Wu, H; Xiong, G; Zhang, Z | 1 |
| Ding, L; Feng, J; Hu, C; Hu, X; Li, Q; Liu, X; Luo, R; Qin, S; Shi, Y; Song, Y; Sun, Y; Tan, F; Wang, D; Wang, J; Wang, Y; Xv, N; Zhang, L; Zhang, S; Zhou, C; Zhou, J | 1 |
| Jin, J; Liu, BZ; Wu, ZM | 1 |
| Cai, XH; Feng, CJ; Huang, CY; Liu, XK; Lu, Y; Wang, L; Wang, Y; Wang, YS; Xu, Y; Yao, WX; Yu, P; Zhou, J; Zhu, WJ | 1 |
| Li, X; Lv, J; Nong, J; Qin, N; Wang, J; Wu, Y; Yang, X; Zhang, H; Zhang, Q; Zhang, S; Zhang, X | 1 |
| Ni, J; Zhang, L | 1 |
| Dong, XR; Li, K; Li, QW; Li, ZY; Liu, L; Ma, H; Meng, R; Wu, G; Zhang, S; Zhou, FZ; Zhou, Y | 1 |
| Li, LW; Xiong, HX; Zhang, HX | 1 |
| Fan, Q; Huang, J; Liu, W; Liu, Y; Lu, P; Ma, C; Sun, Y; Tan, F; Ying, J | 1 |
| Du, H; Guo, L; He, L; Huang, H; Jiang, J; Li, M; Li, Y; Luan, M; Ma, C; Qin, S; Ruan, Y; Shen, L; Zhang, X | 1 |
| Fan, Q; Guo, L; Hu, S; Huang, J; Li, W; Ling, Y; Liu, W; Liu, Y; Lu, P; Ma, C; Niu, H; Wang, X; Ying, J | 1 |
| Ma, A; Shi, J; Wang, D; Yang, J; Zhai, Q; Zhang, C; Zhang, H; Zhang, X | 1 |
| Carbonnaux, M; Couraud, S; Meert, AP; Peters, M; Scherpereel, A; Souquet, PJ | 1 |
| Jiang, X; Wang, W; Zhang, Y | 1 |
| Ding, L; Ding, Z; He, J; Hou, M; Huang, M; Li, L; Liang, M; Liu, Y; Lu, Y; Ren, L; Tan, F; Xiang, J; Xiong, W; Yu, Q; Zhou, L; Zhou, X; Zhu, J | 1 |
| Bai, C; Chen, G; Ding, C; Feng, J; Gu, A; Han, B; He, J; Hu, X; Huang, C; Jian, H; Jiao, S; Li, F; Ling, Y; Liu, X; Luo, H; Luo, R; Pang, Q; Shi, Y; Shu, Y; Sun, Y; Wang, C; Wang, Z; Wu, M; Yang, Y; Zhang, S; Zhang, Y; Zhao, H; Zhao, Q; Zhou, C | 1 |
| Jin, Y; Lou, G; Shao, Y; Shi, X; Tong, X; Wu, X; Yu, X; Zhang, Y | 1 |
| Che, J; Li, H; Li, Z; Lu, C; Luo, H; Wang, J; Yang, H; Yue, S; Zhang, T; Zhang, Y; Zhu, M; Zhuang, X | 1 |
| Hu, M; Qian, K; Wang, R; Yao, S; Zhang, Y; Zhi, X | 1 |
| Chen, J; Ding, L; Hu, X; Liu, J; Shentu, J; Tan, F; Wang, Y; Wu, G; Wu, L; Xu, W; Zhou, H; Zhu, M | 1 |
| Chai, Y; Zhu, Z | 1 |
| Fang, S; Han, X; Tang, N; Wang, Z; Zhang, Q | 1 |
| Biaoxue, R; Hua, L; Shuanying, Y; Wenlong, G | 1 |
| Song, Z; Wang, W; Zhang, Y | 1 |
| Ding, L; Fu, J; Lu, S; Tan, F; Wu, B; Ye, M | 1 |
| Gao, QL; Li, L; Li, QJ; Liu, HM; Ma, XH; Shi, B; Tian, TD | 1 |
| Song, Y; Yuan, DM | 1 |
| Liu, X; Shi, Y; Xu, J; Yang, S; Zhang, X | 1 |
| Fan, Y; Fang, L; Gong, L; Han, N; Huang, Z; Lu, H; Qin, J; Qiu, G; Xie, F; Xu, Y | 1 |
| Qu, J; Qu, Q; Wang, YN; Wei, W; Xiang, DX; Xu, P; Yang, R | 1 |
| Chen, G; Huang, X; Huang, Y; Kang, S; Miao, S; Wu, M; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H | 1 |
| Dong, Z; Gao, H; Hu, H; Li, X; Liu, B; Liu, X; Liu, Y; Shi, W; Sun, Y; Tang, C; Xu, H; Zhu, G | 1 |
| Chen, G; Cheng, Y; Feng, J; Hu, C; Huang, C; Huang, Y; Liu, X; Lu, S; Song, Y; Tan, FL; Wu, G; Wu, YL; Yan, HH; Yang, JJ; Zhang, L; Zhong, W; Zhou, C | 1 |
| Chen, X; Chen, Z; Kong, R; Li, Y; Lu, D; Niu, K; Sun, J; Wang, Y; Xia, L | 1 |
| Guo, R; Jin, S; Min, H; Shu, Y; Wen, W; Wu, H; Xu, T; Zhang, Z | 1 |
| Chen, GY; Ding, CM; Ding, LM; Feng, JF; Han, BH; Han, XH; Li, K; Li, W; Lin, YC; Liu, XQ; Liu, YP; Ma, ZY; Ren, XL; Shi, YK; Shu, YQ; Song, W; Song, X; Song, Y; Sun, Y; Tan, FL; Wang, L; Wu, N; Yao, C; Ye, XQ; Yu, P; Zhang, HL; Zhang, SC; Zhao, SJ | 1 |
| Chen, Z; Feng, X; Gao, Y; He, J; Li, X; Liu, T; Lv, Z; Pan, H; Wang, Y; Xie, S; Yang, W; Yang, X; Zhang, J | 1 |
| Li, Z; Lu, C; Ma, L; Wang, J; Zhang, K; Zhang, T; Zhang, Y; Zhu, M; Zhuang, X | 1 |
| Chen, H; Deng, Y; Ding, L; Guo, J; Huang, X; Li, H; Tan, F; Wang, Y; Yang, G; Yu, B; Yu, P | 1 |
| Fan, T; Liu, XL; Song, YJ; Wei, YN; Yang, H; Zhou, J | 1 |
| Huang, A; Lin, Z; Liu, T; Ma, H; Yao, J; Zhang, S; Zhang, T | 1 |
| Han, R; He, Y; Jiao, L; Li, L; Wang, Y; Zheng, J | 1 |
| Cao, J; Hu, J; Lv, W; Lv, X; Wang, L; Xia, P | 1 |
| Chen, M; Tong, B; Wang, M; Xing, J; Xu, Y; Zhao, J; Zhong, W | 1 |
| Gao, F; Jiang, AY; Luo, HL; Lv, YF; Zhang, J | 1 |
| Bao, Y; Chen, Q; Liu, L; Sun, X; Wang, Y; Xu, Y | 1 |
| Chen, G; Du, KQ; Lv, TF; Song, Y; Song, ZB; Wang, WX; Xu, CW; Zhu, YC; Zhuang, W | 1 |
| Chen, XY; Jiang, JF; Zhong, DF | 1 |
| Fan, T; Zhou, JY | 1 |
| Che, X; Hou, K; Hu, X; Kang, J; Liu, Y; Qu, X; Wang, J; Wang, Y; Zhang, T; Zheng, C | 1 |
| Che, X; Fan, Y; Hou, K; Hu, X; Kang, J; Liu, Y; Qu, X; Wang, J; Zhang, T; Zhang, Y; Zhao, H; Zheng, C | 1 |
| Chen, L; Li, J; Ma, J; Maiolino, P; Xiao, Y; Yan, JH | 1 |
| Cui, J; Li, T; Li, Y; Su, D; Zhang, Y | 1 |
| Ding, L; Liang, S; Ma, Y; Tan, F; Wang, M; Xu, Y | 1 |
| Hao, X; Hu, X; Li, J; Liu, Y; Shi, Y; Wang, Y; Zhou, L; Zhou, S | 1 |
| Gu, P; Hu, F; Hu, P; Li, C; Nie, W; Shen, Y; Wang, H; Wang, S; Xu, J; Zhang, B; Zhang, X; Zhang, Y | 1 |
| Li, XF; Liu, GF; Miao, YY; Yu, SN; Zhang, SH | 1 |
| Dai, L; Lu, L; Lv, D; Su, X | 1 |
| Chen, J; Wang, J | 1 |
| Jing, Z; Wang, XJ; Zhang, N; Zhou, RJ | 1 |
| Fang, Y; Pan, HM; Ren, YL; Sheng, J; Zhou, XY | 1 |
| Han, B; Qiao, R; Wang, S; Xu, J; Zhang, B; Zhang, L; Zhang, Y; Zhao, Y | 1 |
| Chen, H; Chen, M; Deng, W; Gan, H; Jin, L; Lin, Z; Liu, J; Liu, T; Lu, W; Wang, S; Zhang, F; Zhang, H | 1 |
| Ji, YX; Nie, KK; You, YH; Zhu, C | 1 |
| Guo, C; Li, R; Wu, K | 1 |
| Guan, Y; Guo, H; Li, Y; Shi, J; Song, Z; Yao, M; Zhang, X | 1 |
| Liu, X; Shi, F; Su, L; Sun, W; Sun, X; Wang, Y; Yao, S; Zhang, Y | 1 |
| Li, K; Li, Q; Li, Z; Liu, L; Meng, R; Wu, G; Zhang, S; Zhou, F; Zhou, Y | 1 |
| Liu, L; Lou, H; Ruan, Z; Shen, Y; Zheng, M; Zhou, J | 1 |
| Cui, J; Li, Y; Liu, R; Qi, Q; Xu, L; Zhang, Y | 1 |
| Jin, B; Liu, J; Liu, Y; Qu, X; Su, H | 1 |
| Chen, G; Li, XL; Lv, T; Song, Y; Wang, WX; Xu, CW; Zhu, YC; Zhuang, W | 1 |
| Cao, Z; Ding, X; Lin, G; Liu, D; Su, B; Wang, N; Wu, C; Xu, W; Zhou, X | 1 |
| Chuang, Q; Heng, W; Mingzhe, X; Shangli, C; You, C | 1 |
| Pan-Pan, L; Qing, L; Yang, F; Ye, H; Yue-Yun, C; Zhen-Yu, D | 1 |
| Abudula, M; Chen, Y; Chen, Z; Li, C; Yu, Y; Zhang, Y | 1 |
| Fang, MY; Fang, Y; Lei, L; Li, JL; Lv, TF; Song, Y; Wang, H; Wang, LP; Wang, WX; Wang, XJ; Xu, CW; Zhang, YB; Zhu, YC; Zhuang, W | 2 |
| Hu, ZY; Wang, GH | 1 |
| He, X; Jia, Y; Jiang, Y; Li, Z; Qiu, Y | 1 |
| Chen, J; Li, X; Liu, H; Liu, M; Zhang, H | 1 |
| Chen, P; Cheng, J; Guan, S; Sun, J; Zhao, Q | 1 |
| Bai, L; Bai, R; Chen, N; Cui, J; Han, F; Li, J; Li, W; Qian, L; Yu, Y; Zhao, Y | 1 |
| An, G; Cheng, G; Ding, C; Ding, L; He, X; Hu, X; Jiang, D; Li, X; Li, Y; Liang, L; Liu, J; Mao, L; Su, W; Wang, H; Wang, Y; Wu, J; Zang, A; Zhang, C; Zhang, L; Zhang, S; Zhang, Y; Zhao, M; Zhong, D | 1 |
| Jha, RK; Jia, M; Li, K; Liu, Y; Zhan, W; Zhao, Y; Zhou, L | 1 |
| Chen, YJ; Jiang, HG; Jin, J; Li, J; Li, MY; Shu, Y; Wu, JN; Xiang, M; Zhu, YM | 1 |
| Huang, W; Kong, H; Liu, P; Peng, LY; Xie, WP; Yang, MX; Yu, M; Zhou, H | 1 |
| Chen, S; Gu, Y; Li, S; Lin, X; Liu, M; Ouyang, M; Qin, Y; Xiang, J; Xie, X; Zhou, C | 1 |
| Che, X; Chen, Y; Cheng, Y; Deng, M; Hou, K; Hu, X; Liu, Y; Qu, X; Wang, Y; Wu, J; Yan, H; Yang, Y; Zhang, Y; Zou, D | 1 |
| Bu, H; Chen, X; Cui, JZ; Guo, L; Guo, XS; Han, WX; He, JY; Li, C; Meng, ZQ; Wang, X; Yan, LT; Zhao, Y; Zou, YL | 1 |
| Chen, P; Ding, L; Du, D; Fang, M; Hua, Y; Jiang, W; Jing, Z; Luo, H; Ma, L; Song, Y; Tian, Z; Wang, J; Wu, S; Xie, R; Zhou, R | 1 |
| Ding, WJ; Dong, QH; Wang, W; Yang, HH; Zhu, J | 1 |
| Li, YM; Mao, L; Sun, G; Xu, G; Yuan, M; Zhao, J | 1 |
| Dou, Z; Fang, G; Han, X; Huo, R; Li, X; Liu, W; Shang, Y; Shi, X; Wang, K; Yuan, S; Zang, A; Zhang, J; Zhang, L; Zhang, Y | 1 |
| Lian, X; Liao, M; Quan, J; Wang, G; Wu, Y; Xie, W; Yang, ZZ; Zhang, Z | 1 |
| Feng, LX; Ge, H; Wang, J; Yu, Z; Zhang, LW; Zhang, Y | 1 |
| Bates, V; Boland, A; Chaplin, M; Dundar, Y; Green, JA; Greenhalgh, J; Vecchio, F | 1 |
| Chen, WJ; Ding, Y; Liu, H; Liu, YM; Sun, HL; Xu, YY; Ying, SP | 1 |
| Chen, DS; Jin, LL; Li, S; Wang, YL; Wu, ZZ; Xiao, M; Zhao, X | 1 |
| He, T; Li, C; Li, X; Luo, Y; Shi, X; Zhao, J; Zu, Y | 1 |
| Liu, Q; Wu, L; Zhang, S | 1 |
| Ji, YX; Mu, XY; Sun, L; Zhang, L | 1 |
| Jiang, Z; Li, Y; Pan, Z; Sun, H; Wang, C; Zhang, J; Zhang, Y | 1 |
| Jia, Y; Li, W; Peng, Y; Sun, C; Yang, Y; Zhao, H; Zheng, J | 1 |
| Chen, H; Ding, L; He, X; Ma, Y; Shen, Z; Wang, Y; Yang, M; Yuan, X | 1 |
| Gao, X; Li, H; Lian, S; Lin, J; Song, C | 1 |
| Chen, K; Chen, P; Dai, CH; Li, J; Shi, ZH; Su, JY; Wang, Y; Wu, JN | 1 |
| Cui, J; Jiang, P; Li, Y; Wang, X; Zhang, Y | 1 |
| Du, X; Liu, W; Wang, Z; Xiong, X; Yang, L; Yang, P; Zhang, Y; Zhou, C | 1 |
| Chen, G; Chen, Y; Li, W; Liu, B; Lyu, X; Ming, Z; Shi, J; Sun, R; Yang, S; Yang, X; Yuan, B; Yuan, J; Zeng, L; Zhao, N | 1 |
| Bai, H; Dong, G; Du, N; Duan, J; Gao, L; Guo, J; Huang, Y; Ji, D; Li, B; Li, L; Li, Q; Li, X; Liu, Z; Lv, Q; Wan, R; Wang, J; Wang, T; Wang, Z; Xu, J; Yang, Z; Zang, A; Zhang, C; Zhang, J; Zhao, J; Zhao, Y; Zhong, D; Zhong, J | 1 |
| Li, B; Liao, H; Wang, Y; Zhou, B | 1 |
13 review(s) available for quinazolines and icotinib
| Article | Year |
|---|---|
[Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
Topics: Antineoplastic Agents; Crown Ethers; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Glucuronosyltransferase; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2013 |
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Crown Ethers; Data Collection; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Markov Chains; Mutation; Probability; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Icotinib: activity and clinical application in Chinese patients with lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; China; Clinical Trials, Phase III as Topic; Crown Ethers; Drug Interactions; ErbB Receptors; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines; Randomized Controlled Trials as Topic | 2014 |
Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crown Ethers; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diarrhea; Disease-Free Survival; ErbB Receptors; Exanthema; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pruritus; Quinazolines; Treatment Outcome | 2016 |
Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis.
Topics: Alleles; Amino Acid Substitution; Antineoplastic Agents; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Odds Ratio; Publication Bias; Quinazolines; Treatment Outcome | 2017 |
Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Crown Ethers; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Network Meta-Analysis; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
[Metabolic research of domestically developed small molecule tyrosine kinase inhibitors].
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Benzofurans; China; Crown Ethers; Drug Interactions; Humans; Indoles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines | 2016 |
Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Network Meta-Analysis; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic | 2019 |
Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an
Topics: Adenocarcinoma of Lung; Adult; Chemotherapy, Adjuvant; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Male; Oncogene Proteins, Fusion; Pneumonectomy; Precision Medicine; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Rad51 Recombinase; Thoracoscopy; Treatment Outcome | 2019 |
Icotinib: efficacy in different solid tumors and gene mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Neoplasms; Quinazolines | 2020 |
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Topics: Afatinib; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bias; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Pemetrexed; Progression-Free Survival; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2021 |
27 trial(s) available for quinazolines and icotinib
| Article | Year |
|---|---|
Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Folliculitis; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Proto-Oncogene Proteins p21(ras); Quinazolines; Treatment Outcome | 2011 |
Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Male; Middle Aged; Quinazolines | 2011 |
Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Crown Ethers; Disease-Free Survival; Double-Blind Method; Drug Evaluation, Preclinical; ErbB Receptors; Female; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Tyrosine | 2012 |
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2013 |
Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects.
Topics: Adult; Antineoplastic Agents; Cross-Over Studies; Crown Ethers; Dose-Response Relationship, Drug; Food-Drug Interactions; Humans; Male; Quinazolines; Xenograft Model Antitumor Assays; Young Adult | 2014 |
Personalized biomarkers to monitor disease progression in advanced non-small-cell lung cancer patients treated with icotinib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Monitoring; Electrophoresis, Polyacrylamide Gel; Female; Humans; Immunity, Humoral; Inflammation; Lung Neoplasms; Male; Middle Aged; Precision Medicine; Quinazolines; Time Factors | 2015 |
Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Brain; Brain Neoplasms; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis | 2014 |
Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect.
Topics: Administration, Oral; Adult; Age Factors; Antineoplastic Agents; Asian People; China; Cross-Over Studies; Crown Ethers; Cytochrome P-450 CYP2C19; Food-Drug Interactions; Gastrointestinal Absorption; Healthy Volunteers; Humans; Models, Biological; Nonlinear Dynamics; Pharmacogenetics; Polymorphism, Genetic; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Serum Albumin; Serum Albumin, Human; Young Adult | 2015 |
A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Crown Ethers; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines | 2015 |
Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Crown Ethers; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Risk Factors; Treatment Outcome | 2015 |
Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; China; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines | 2015 |
Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Consolidation Chemotherapy; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2015 |
The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease-Free Survival; Female; Humans; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2015 |
[Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies | 2015 |
Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study.
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Carcinoma, Squamous Cell; Crown Ethers; ErbB Receptors; Esophageal Neoplasms; Female; Follow-Up Studies; Gene Amplification; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate; Young Adult | 2016 |
Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cranial Irradiation; Crown Ethers; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies | 2016 |
A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Quinazolines | 2016 |
Efficacy and influence factors of icotinib hydrochloride in treating advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2017 |
Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiosurgery | 2017 |
Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Quinazolines; Treatment Outcome | 2017 |
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Crown Ethers; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Quinazolines | 2017 |
Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study.
Topics: Adult; Crown Ethers; Double-Blind Method; Female; Humans; Male; Middle Aged; Ointments; Psoriasis; Quinazolines | 2019 |
Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Crown Ethers; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Survival Analysis | 2019 |
Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Pyridines; Quinazolines; Research Design; Young Adult | 2020 |
Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial.
Topics: Adult; Aged; Alleles; Amino Acid Substitution; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Young Adult | 2020 |
Icotinib With Concurrent Radiotherapy vs Radiotherapy Alone in Older Adults With Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Combined Modality Therapy; Crown Ethers; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Neoplasm Staging; Quinazolines; Treatment Outcome | 2020 |
Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Circulating Tumor DNA; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2022 |
129 other study(ies) available for quinazolines and icotinib
| Article | Year |
|---|---|
Metabolite identification of a new antitumor agent icotinib in rats using liquid chromatography/tandem mass spectrometry.
Topics: Animals; Antineoplastic Agents; Bile; Chromatography, Liquid; Crown Ethers; Feces; Magnetic Resonance Spectroscopy; Male; Molecular Structure; Molecular Weight; Quinazolines; Rats; Rats, Wistar; Reference Standards; Solid Phase Extraction; Tandem Mass Spectrometry; Urinalysis | 2008 |
Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry.
Topics: Antineoplastic Agents; Chromatography, Liquid; Crown Ethers; Humans; Quinazolines; Sensitivity and Specificity; Tandem Mass Spectrometry | 2009 |
Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Exons; Female; Humans; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Quinazolines; RNA, Messenger | 2011 |
Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry.
Topics: Animals; Antineoplastic Agents; Chromatography, Liquid; Crown Ethers; Feces; Humans; Male; Metabolic Networks and Pathways; Quinazolines; Rats; Tandem Mass Spectrometry; Young Adult | 2011 |
Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Crown Ethers; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2012 |
Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers.
Topics: Adult; Alleles; Antineoplastic Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Crown Ethers; Cytochrome P-450 CYP2C19; Genotype; Humans; Male; Protein Kinase Inhibitors; Quinazolines | 2012 |
[Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intra-Arterial; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nimustine; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Skin Diseases; Survival Analysis; Treatment Outcome | 2012 |
[Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting].
Topics: Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoglobulins, Intravenous; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Precision Medicine; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quality Control; Quinazolines | 2012 |
[Effects of icotinib hydrochloride on the proliferation and apoptosis of human lung cancer cell lines].
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Crown Ethers; ErbB Receptors; Gefitinib; Humans; Inhibitor of Apoptosis Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Survivin | 2012 |
[Clinical observation of icotinib hydrochloride for patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diarrhea; Disease Progression; ErbB Receptors; Exanthema; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate | 2012 |
Spared pre-irradiated area in pustular lesions induced by icotinib showing decreased expressions of CD1a+ langerhans cells and FGFR2.
Topics: Acneiform Eruptions; Adenocarcinoma; Adenocarcinoma of Lung; Antigens, CD1; Antineoplastic Agents; Biopsy; Blister; Chemotherapy, Adjuvant; Crown Ethers; Dose Fractionation, Radiation; Down-Regulation; Drug Eruptions; Enzyme Inhibitors; ErbB Receptors; Face; Folliculitis; Humans; Immunohistochemistry; Ki-67 Antigen; Langerhans Cells; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; Skin; Thoracic Wall | 2013 |
[Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Safety; Survival Analysis | 2013 |
Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Crown Ethers; ErbB Receptors; G1 Phase; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-cbl; Quinazolines; Signal Transduction | 2013 |
Letter to the editor. Probing gender-specific change in IgG1 Fc-galactosylation in non-small cell lung cancer patients treated with epidermal growth factor receptor inhibitor.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Galactose; Humans; Immunoglobulin Fc Fragments; Immunoglobulin G; Lung Neoplasms; Male; Mass Spectrometry; Quinazolines; Sex Factors | 2013 |
Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Crown Ethers; Dose-Response Relationship, Drug; Down-Regulation; ErbB Receptors; Humans; Mice; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Quinazolines; Signal Transduction; Skin Neoplasms | 2013 |
A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crown Ethers; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prognosis; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2013 |
[Clinical effects for patients with recurrent advanced non-small cell lung cancer treated with icotinib hydrochloride].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Recurrence; Retrospective Studies; Survival Analysis; Treatment Failure | 2013 |
[Clinical observation of icotinib hydrochloride in first-line therapy for pulmonary adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Crown Ethers; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Treatment Outcome | 2013 |
Icotinib: kick-starting the Chinese anticancer drug industry.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2013 |
Dramatic response to high-dose icotinib in a lung adenocarcinoma patient after erlotinib failure.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Crown Ethers; Docetaxel; Drug Dosage Calculations; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Remission Induction; Salvage Therapy; Taxoids; Treatment Failure | 2014 |
Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Quinazolines; Retrospective Studies | 2014 |
T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines | 2014 |
Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Phenotype; Quinazolines; Retrospective Studies | 2014 |
Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Crown Ethers; Disease-Free Survival; ErbB Receptors; Humans; Kaplan-Meier Estimate; Middle Aged; Quinazolines; Retrospective Studies; Treatment Outcome | 2014 |
Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2.
Topics: Animals; ATP-Binding Cassette Transporters; Cell Line, Tumor; Crown Ethers; Drug Resistance, Multiple; Glutamates; Guanine; HEK293 Cells; Humans; Mice; Mice, Nude; Pemetrexed; Quinazolines; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2014 |
Effective treatment with icotinib in primary adenoid cystic carcinoma of the lung with liver metastasis.
Topics: Adult; Biopsy; Carcinoma, Adenoid Cystic; Crown Ethers; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Quinazolines; Tomography, X-Ray Computed | 2014 |
Induction of Tca8113 tumor cell apoptosis by icotinib is associated with reactive oxygen species mediated p38-MAPK activation.
Topics: Apoptosis; Cell Death; Cell Line, Tumor; Crown Ethers; Enzyme Activation; Humans; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Quinazolines; Reactive Oxygen Species | 2014 |
Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; China; Chromatography, High Pressure Liquid; Crown Ethers; Cytochrome P-450 CYP2C19; Disease-Free Survival; Drug Eruptions; Female; Genes, erbB-1; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Tandem Mass Spectrometry | 2014 |
A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retreatment; Retrospective Studies; Risk Factors; Treatment Outcome; Young Adult | 2014 |
In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Crown Ethers; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Humans; Inhibitory Concentration 50; Lung Neoplasms; Paclitaxel; Quinazolines; Resting Phase, Cell Cycle; Signal Transduction | 2015 |
EGFR inhibitor-driven endoplasmic reticulum stress-mediated injury on intestinal epithelial cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line; Crown Ethers; Diarrhea; Endoplasmic Reticulum Stress; ErbB Receptors; Gefitinib; Intestinal Mucosa; Protein Kinase Inhibitors; Quinazolines; Rats | 2014 |
[Cetuximab in combination with icotinib overcomes the acquired resistance caused by EGFR T790M mutation in non-small cell lung cancer].
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Crown Ethers; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Genes, erbB-1; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Quinazolines; Signal Transduction | 2014 |
Icotinib hydrochloride enhances the effect of radiotherapy by affecting DNA repair in colorectal cancer cells.
Topics: Adenocarcinoma; Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Survival; Colorectal Neoplasms; Crown Ethers; DNA Repair; Flow Cytometry; Fluorescent Antibody Technique; HCT116 Cells; Heterografts; HT29 Cells; Humans; Mice; Mice, Nude; Quinazolines; Radiation-Sensitizing Agents | 2015 |
Icotinib plus gemcitabine for metastatic pancreatic cancer: a case report.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Crown Ethers; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Targeted Therapy; Pancreatic Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2015 |
Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling.
Topics: Antineoplastic Agents; Area Under Curve; Computer Simulation; Crown Ethers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Ketoconazole; Male; Microsomes, Liver; Models, Biological; Quinazolines; Rifampin | 2015 |
Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate | 2015 |
[Comparison of the Efficacy and Safety of Icotinib with Standard Second-line
Chemotherapy in Previously Treated Advanced Non-small Cell Lung Cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Quinazolines; Retreatment; Treatment Outcome | 2015 |
Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Outcome Assessment, Health Care; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2015 |
[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Consensus; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Quinazolines | 2015 |
Systematic Analysis of Icotinib Treatment for Patients with Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Humans; Lung Neoplasms; Meta-Analysis as Topic; Neoplasm Staging; Prognosis; Quinazolines | 2015 |
Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diabetes Mellitus, Type 2; Disease-Free Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
Evaluation of melanoma antigen gene A3 expression in drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced nonsmall cell lung cancer treatment.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2015 |
Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diphosphonates; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pamidronate; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2016 |
[The CK2 inhibitor quninalizarin enhances the anti-proliferative effect of icotinib on EGFR-TKIs-resistant cell lines and its underlying mechanisms].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Analysis of Variance; Anthraquinones; Apoptosis; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crown Ethers; Down-Regulation; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Lung Neoplasms; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2016 |
Investigation on the protein-binding properties of icotinib by spectroscopic and molecular modeling method.
Topics: Antineoplastic Agents; Binding Sites; Circular Dichroism; Crown Ethers; ErbB Receptors; Humans; Models, Molecular; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Serum Albumin; Spectrometry, Fluorescence; Thermodynamics | 2016 |
Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; China; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Treatment Outcome | 2016 |
Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Crown Ethers; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gene Amplification; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Middle Aged; Predictive Value of Tests; Proto-Oncogene Mas; Quinazolines | 2016 |
Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China.
Topics: Carcinoma, Non-Small-Cell Lung; China; Clinical Trials as Topic; Cost-Benefit Analysis; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Male; Markov Chains; Mutation; Quinazolines | 2016 |
Inequalities in lung cancer: a world of EGFR.
Topics: Afatinib; Crown Ethers; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Geography; Global Health; Health Care Costs; Health Equity; Health Services Accessibility; Healthcare Disparities; Humans; Lung Neoplasms; Medical Oncology; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Surveys and Questionnaires; United States | 2016 |
[Clinical Analysis of Icotinib on Beneficiary of
Advanced Non-small Cell Lung Cancer with EGFR Common Mutation].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies | 2016 |
[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment
(2016 version)].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Consensus; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quinazolines | 2016 |
Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Crown Ethers; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Gene Library; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2016 |
Allosteric activation of midazolam CYP3A5 hydroxylase activity by icotinib - Enhancement by ketoconazole.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Crown Ethers; Cytochrome P-450 CYP3A; Dogs; Dose-Response Relationship, Drug; Drug Interactions; Haplorhini; Humans; In Vitro Techniques; Ketoconazole; Mice; Microsomes, Liver; Midazolam; Quinazolines; Rats; Species Specificity; Substrate Specificity | 2016 |
Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome | 2016 |
Complete remission of liver metastasis in a lung cancer patient with epidermal growth factor mutation achieved with Icotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Male; Mutation; Pulmonary Surgical Procedures; Quinazolines; Remission Induction; Treatment Outcome | 2016 |
Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
Topics: A549 Cells; Angiogenesis Inhibitors; Animals; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Docetaxel; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice, Nude; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Precision Medicine; Prognosis; Quinazolines; Reagent Kits, Diagnostic; Sensitivity and Specificity; Treatment Outcome | 2017 |
Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Computer Simulation; Cost-Benefit Analysis; Crown Ethers; Disease-Free Survival; Drug Costs; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Models, Economic; Molecular Targeted Therapy; Mutation; Pemetrexed; Precision Medicine; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines; Time Factors; Treatment Outcome | 2017 |
[Precision first-line therapy for advanced non-small-cell lung cancer patients harboring EGFR mutation].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Efficacy of icotinib in lung squamous-cell cancer: A real-world experience from single institution.
Topics: Aged; Antineoplastic Agents; Crown Ethers; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Squamous Cell; Quinazolines; Retrospective Studies | 2017 |
Droplet digital PCR improved the EGFR mutation diagnosis with pleural fluid samples in non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Particle Size; Pleural Effusion; Polymerase Chain Reaction; Quinazolines | 2017 |
Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Crown Ethers; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy | 2018 |
Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; ErbB Receptors; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Pemetrexed; Protein-Tyrosine Kinases; Quinazolines | 2017 |
Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; China; Crown Ethers; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Pneumonectomy; Point Mutation; Postoperative Period; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion | 2017 |
Metabolic Pathway of Icotinib In Vitro: The Differential Roles of CYP3A4, CYP3A5, and CYP1A2 on Potential Pharmacokinetic Drug-Drug Interaction.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Lung Neoplasms; Metabolic Networks and Pathways; Microsomes, Liver; Quinazolines | 2018 |
Icotinib inhibits EGFR signaling and alleviates psoriasis-like symptoms in animal models.
Topics: Animals; Cell Line, Tumor; Crown Ethers; Epithelial Cells; ErbB Receptors; Female; Guinea Pigs; Humans; Mice; Mice, Inbred ICR; Mitosis; Models, Animal; Neovascularization, Pathologic; Psoriasis; Quinazolines; Signal Transduction | 2018 |
Lung Cancer with Concomitant Double Gene Mutation.
Topics: Adenocarcinoma; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Biopsy; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Nivolumab; Pemetrexed; Positron Emission Tomography Computed Tomography; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2018 |
53BP1 loss suppresses the radiosensitizing effect of icotinib hydrochloride in colorectal cancer cells.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Colorectal Neoplasms; Crown Ethers; DNA Damage; ErbB Receptors; HCT116 Cells; Histones; Humans; Quinazolines; Radiation-Sensitizing Agents; S Phase; Tumor Suppressor p53-Binding Protein 1 | 2018 |
Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib.
Topics: Acrylamides; Adenocarcinoma of Lung; Adult; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Cohort Studies; Crizotinib; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Amplification; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis | 2018 |
Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Female; Hand-Foot Syndrome; Humans; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quinazolines | 2018 |
Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Count; Crizotinib; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Rearrangement; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplastic Cells, Circulating; Prognosis; Quinazolines | 2018 |
Icotinib and whole-brain radiotherapy for the treatment in patients with brain metastases from EGFR-mutant nonsmall cell lung cancer: A retrospective study.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; China; Combined Modality Therapy; Cranial Irradiation; Crown Ethers; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radiotherapy Dosage; Retrospective Studies | 2018 |
Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Crown Ethers; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Thalidomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Remission Induction | 2018 |
Marked Response to Icotinib in Lung Squamous Cell Carcinoma with EGFR Wild-Type.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Male; Quinazolines; Treatment Outcome | 2018 |
Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Interleukin-6; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; STAT3 Transcription Factor | 2018 |
Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; NF-kappa B; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Quinazolines; RNA Interference; RNA, Small Interfering; Up-Regulation | 2019 |
Validation of an LC-MS/MS method for simultaneous determination of icotinib and its four major circulating metabolites in human plasma and its application in a pharmacokinetic study.
Topics: Adult; Chromatography, Liquid; Crown Ethers; Drug Stability; Humans; Limit of Detection; Linear Models; Middle Aged; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry | 2018 |
Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts.
Topics: Adenocarcinoma of Lung; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Crown Ethers; Disease Models, Animal; Drug Therapy, Combination; ErbB Receptors; Female; Humans; Mice; Mutation; Pemetrexed; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2018 |
Efficacy of icotinib in advanced lung squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Crown Ethers; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome | 2018 |
Clinicopathologic characteristics and outcome of patients with different EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2019 |
Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Consolidation Chemotherapy; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Retrospective Studies; Survival Analysis | 2019 |
Nonsmall cell lung cancer with rare exon 7 p.A289V mutation in the EGFR gene responds to Icotinib treatment: A case report.
Topics: Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Tomography, X-Ray Computed | 2018 |
Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report.
Topics: Acrylamides; Adenocarcinoma of Lung; Aged; Alleles; Amino Acid Substitution; Aniline Compounds; Antineoplastic Agents; Biomarkers; Brain Neoplasms; Combined Modality Therapy; Crown Ethers; ErbB Receptors; Humans; Magnetic Resonance Imaging; Male; Mutation; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Retreatment; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
20(S)-ginsenoside Rg3 sensitizes human non-small cell lung cancer cells to icotinib through inhibition of autophagy.
Topics: Animals; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Crown Ethers; Drug Synergism; Female; Ginsenosides; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Quinazolines; Xenograft Model Antitumor Assays | 2019 |
[Clinical effect of icotinib in treatment of elderly advanced non-small cell lung cancer patients with EGFR mutations].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quinazolines | 2019 |
Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Young Adult | 2019 |
Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Crown Ethers; Drug Synergism; Humans; Lung Neoplasms; Mice; Mice, Nude; Pemetrexed; Quinazolines | 2019 |
Icotinib plus osimertinib overcome epidermal growth factor receptor 19del/T790 M/C797S/V834L quadruplet resistance mutation in a patient with non-small cell lung cancer.
Topics: Acrylamides; Aged; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Quinazolines | 2019 |
Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines | 2019 |
Angio-associated migratory cell protein interacts with epidermal growth factor receptor and enhances proliferation and drug resistance in human non-small cell lung cancer cells.
Topics: A549 Cells; Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Crown Ethers; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Knockdown Techniques; HEK293 Cells; Heterografts; Humans; Lung Neoplasms; Mice; Phosphorylation; Quinazolines; Transfection; Tumor Burden | 2019 |
Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines.
Topics: Adenocarcinoma of Lung; Anthraquinones; Antineoplastic Agents; Apoptosis; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Crown Ethers; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2019 |
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
Topics: Acrylamides; Afatinib; Aged; Aniline Compounds; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Fatal Outcome; Female; Follow-Up Studies; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines | 2019 |
Identification of a Novel Icotinib-Sensitive EGFR-SEPTIN14 Fusion Variant in Lung Adenocarcinoma by Next-Generation Sequencing.
Topics: Adenocarcinoma of Lung; Crown Ethers; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2019 |
Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; Crown Ethers; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; G2 Phase Cell Cycle Checkpoints; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; RNA, Small Interfering | 2019 |
Primary resistance to icotinib in a patient with lung adenocarcinoma harboring EGFR L858R and Q787k mutations.
Topics: Adenocarcinoma of Lung; Aged; Amino Acid Substitution; Antineoplastic Agents; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Quinazolines; Structure-Activity Relationship; Treatment Outcome | 2019 |
Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2019 |
Icotinib-resistant HCC827 cells produce exosomes with mRNA MET oncogenes and mediate the migration and invasion of NSCLC.
Topics: Antineoplastic Agents, Immunological; Bronchoalveolar Lavage Fluid; Cell Line, Tumor; Cell Movement; Crown Ethers; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Exosomes; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Invasiveness; Oncogenes; Proto-Oncogene Proteins c-met; Quinazolines; RNA, Messenger | 2019 |
Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study.
Topics: Aged; Asian People; Carcinoma, Non-Small-Cell Lung; China; Circulating Tumor DNA; Crown Ethers; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2020 |
Icotinib inhibits proliferation and epithelial-mesenchymal transition of non-small cell lung cancer A549 cells.
Topics: A549 Cells; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Crown Ethers; Drug Screening Assays, Antitumor; Epithelial-Mesenchymal Transition; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Quinazolines | 2019 |
Efficacy of early combination of local radiotherapy and GM-CSF for advanced non-small cell lung cancer treated with icotinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Young Adult | 2020 |
Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.
Topics: Carcinoma, Non-Small-Cell Lung; China; Circulating Tumor DNA; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Regulatory Networks; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Retrospective Studies; Sequence Analysis, DNA | 2020 |
Cost-effectiveness of icotinib versus whole-brain irradiation with or without chemotherapy in EGFR-mutant NSCLC patients with brain metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Cranial Irradiation; Crown Ethers; Disease Progression; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Quality of Life; Quinazolines | 2021 |
Dual Loading of Nanoparticles with Doxorubicin and Icotinib for the Synergistic Suppression of Non-Small Cell Lung Cancer.
Topics: A549 Cells; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crown Ethers; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Synergism; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Nanoparticles; Quinazolines | 2020 |
Bisdemethoxycurcumin Enhances the Sensitivity of Non-small Cell Lung Cancer Cells to Icotinib via Dual Induction of Autophagy and Apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Crown Ethers; Diarylheptanoids; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Quinazolines; Reactive Oxygen Species; Sp Transcription Factors; Voltage-Dependent Anion Channel 1 | 2020 |
Icotinib Attenuates Monocrotaline-Induced Pulmonary Hypertension by Preventing Pulmonary Arterial Smooth Muscle Cell Dysfunction.
Topics: Animals; Cell Movement; Cell Proliferation; Crown Ethers; Disease Models, Animal; Epidermal Growth Factor; ErbB Receptors; Hypertension, Pulmonary; In Vitro Techniques; MAP Kinase Signaling System; Microfilament Proteins; Monocrotaline; Muscle Proteins; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Osteopontin; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pulmonary Artery; Quinazolines; Rats; Signal Transduction; Vascular Remodeling; Ventricular Function, Right; Ventricular Pressure; Vimentin | 2020 |
A first case report of clinical response to targeted therapy in a patient with primary myoepithelial carcinoma of the lung harboring EGFR exon 19 deletion.
Topics: Aged; Antineoplastic Agents; Crown Ethers; Disease-Free Survival; ErbB Receptors; Exons; Gene Deletion; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Myoepithelioma; Quinazolines; Smoking | 2020 |
Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; GRB2 Adaptor Protein; Humans; Lung Neoplasms; Lymecycline; Male; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinase; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2020 |
Detection of genes mutations in cerebrospinal fluid circulating tumor DNA from neoplastic meningitis patients using next generation sequencing.
Topics: Acrylamides; Adult; Aged; Aniline Compounds; Antineoplastic Agents; Circulating Tumor DNA; Class I Phosphatidylinositol 3-Kinases; Crown Ethers; DNA Copy Number Variations; Female; Genes, erbB-1; High-Throughput Nucleotide Sequencing; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Mutation Rate; Proto-Oncogene Proteins c-akt; Quinazolines; Young Adult | 2020 |
[Icotinib combined with radiotherapy for childhood nasopharyngeal carcinoma: A case report and review of the literature].
Topics: Child; Combined Modality Therapy; Crown Ethers; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Prognosis; Quinazolines; Radiotherapy; Radiotherapy Dosage; Treatment Outcome | 2020 |
Design, synthesis and antitumor activity of icotinib derivatives.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Crown Ethers; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Biomarkers, Tumor; China; Crown Ethers; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines | 2020 |
Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer.
Topics: Animals; Autophagosomes; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crown Ethers; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mice, Nude; Microtubule-Associated Proteins; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Protein Kinase Inhibitors; Quinazolines; Sequestosome-1 Protein; Signal Transduction | 2020 |
Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Drug Administration Schedule; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Progression-Free Survival; Quinazolines | 2021 |
Outcomes of icotinib combined with concurrent chemoradiotherapy in locally advanced cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Crown Ethers; Female; Humans; Neoplasm Staging; Quinazolines; Uterine Cervical Neoplasms | 2021 |
Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2021 |
Complete remission following icotinib administration in an advanced ectopic thymic carcinoma patient harbouring the EGFR exon 19 deletion.
Topics: Antineoplastic Agents; Crown Ethers; ErbB Receptors; Exons; Humans; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Sequence Deletion; Thymoma; Thymus Neoplasms | 2021 |
Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report.
Topics: Adenocarcinoma of Lung; Carcinoma, Adenosquamous; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2021 |
Bevacizumab Combined with Icotinib Overcomes Osimertinib Resistance in a Patient of Non-Small Cell Lung Cancer.
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crown Ethers; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Bevacizumab; Carcinoma, Non-Small-Cell Lung; China; Crown Ethers; Drug Therapy, Combination; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies | 2021 |
Icotinib Induces Mechanism-Based Inactivation of Recombinant Human CYP3A4/5 Possibly via Heme Destruction by Ketene Intermediate.
Topics: Activation, Metabolic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Activation; ErbB Receptors; Ethylenes; Heme; Humans; Ketones; Microsomes, Liver; Quinazolines; Recombinant Proteins | 2021 |
Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Crown Ethers; Dose-Response Relationship, Drug; ErbB Receptors; Exons; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2021 |
Chemical Enhancement Effect of Icotinib-Au Complex Studied by Combined Density Functional Theory and Surface-Enhanced Raman Scattering.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; Density Functional Theory; Gold; Humans; Lung Neoplasms; Metal Nanoparticles; Quinazolines; Spectrum Analysis, Raman | 2021 |
Synergistic inhibitory effect of berberine and icotinib on non-small cell lung cancer cells via inducing autophagic cell death and apoptosis.
Topics: Animals; Apoptosis; Autophagic Cell Death; Berberine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Mice; Quinazolines; Signal Transduction | 2021 |
Inhibitory effects of icotinib combined with antiangiogenic drugs in human non-small cell lung cancer xenograft models are better than single target drugs.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crown Ethers; Drug Therapy, Combination; Endostatins; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2022 |
Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Crown Ethers; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry | 2022 |
Essential role for STAT3/FOXM1/ATG7 signaling-dependent autophagy in resistance to Icotinib.
Topics: Autophagy; Autophagy-Related Protein 7; Beclin-1; Cell Line, Tumor; Crown Ethers; ErbB Receptors; Forkhead Box Protein M1; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; STAT3 Transcription Factor | 2022 |
Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report.
Topics: Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Quinazolines | 2022 |